John Meek, MD
Infectious Disease · Lexington, KYNPI 1891796298
Payments from drug & device makers
Across 574 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Shionogi Inc$1K
- Viiv Healthcare Company$1K
- Merck$1K
- Insmed, Inc.$1K
- Astellas Pharma US Inc$863
- plus $4K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 120 | $2,821 |
| Shionogi Inc | 45 | $1,473 |
| Viiv Healthcare Company | 74 | $1,179 |
| Merck | 65 | $1,133 |
| Insmed, Inc. | 48 | $1,017 |
| Astellas Pharma US Inc | 43 | $863 |
| Melinta Therapeutics, LLC | 38 | $609 |
| AbbVie(2 entities) | 23 | $600 |
| Paratek Pharmaceuticals, Inc. | 25 | $563 |
| La Jolla Pharmaceutical Company | 16 | $549 |
| Aimmune Therapeutics, Inc. | 13 | $263 |
| Tetraphase Pharmaceuticals, Inc. | 13 | $222 |
| Johnson & Johnson(2 entities) | 9 | $153 |
| Mayne Pharma Commercial LLC | 8 | $147 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $105 |
| Theratechnologies Inc. | 6 | $99 |
| Ferring Pharmaceuticals Inc. | 6 | $95 |
| Cumberland Pharmaceuticals, Inc. | 3 | $85 |
| Pfizer | 5 | $83 |
| CSL Behring | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Urgo Medical North America, LLC | 1 | $27 |
| Invivyd Inc | 1 | $27 |
| Organogenesis Inc. | 1 | $24 |
| Pharming Healthcare, Inc. | 1 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Biomerieux Inc | 1 | $16 |
| Romark Laboratories, LC | 1 | $13 |
How this compares
$12,331 in reported general payments places this provider in the 80th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Lexington
- Richard GreenbergLexington$18M
- David DoughertyLexington$512K
- Charles RoseLexington$171K
- Marty AllenLexington$40K
- Daniel RodrigueLexington$37K
- Mark DoughertyLexington$12K
- Andrea BanksLexington$11K
- Takako SchaningerLexington$8K
- Andrew AlexanderLexington$7K
- Elizabeth PiercyLexington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.